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ASBMT AND 5 BMT ORGANIZATIONS
ADOPT UNIFIED POLICY STATMENT
A unified policy for legislative and
regulatory advocacy has been adopted
by ASBMT and five other stem cell
therapy and blood and marrow trans-
plant organizations. The coordinated
platform addresses seven areas of
common concern: access to care,
cost of care, patient and donor rights,
confidentiality, clinical research, safety,
and patient and public awareness
and education. The joint policy will
enable the six organizations to act as
a coalition, assisting one another in
addressing legislative and regulatory
issues that affect stem cell collection,
processing, and clinical care.
The organizations, in addition to
ASBMT, are:
• American Association of Blood
Banks (AABB)
• Foundation for the Accreditation of
Cellular Therapy (FACT)
• International Bone Marrow Trans-
plant Registry/Autologous Blood
and Marrow Transplant Registry
(IBMTR/ABMTR)
• International Society for Cellular
Therapy (ISCT)
• National Marrow Donor Program
(NMDP)
“Until now each of the organiza-
tions has pursued its own agenda
and occasionally called upon the oth-
ers for assistance as the need arose,”
said C. Fred LeMaistre, MD, chair of a
task force of representatives of the six
organizations. “Under this new ar-
rangement the organizations remain
independent and can act indepen-
dently, but there’s also a formal struc-
ture and protocol for working to-
gether on legislative and regulatory
issues.”
The joint task force representing
the six organizations was assembled
by John Wingard, MD, while he was
ASBMT president in 2002. During the
past year the task force drafted the
joint policy that was reviewed and
refined by the policy committees and
governing boards of the six organiza-
tions.
“This joint policy acknowledges
that each organization has its own
specific objectives, particular constitu-
ency, and priorities,” said Jeffrey
Chell, MD, chief executive officer for
the NMDP and a member of the task
force. “But, more importantly, it em-
phasizes that we share a common set
of values and beliefs. It is because of
these that the blood and marrow
transplant community can have a uni-
fied agenda for public advocacy.”
Edward Snyder, MD, representing
the AABB on the task force, observed
that “when the interests of patients
and donors are placed at the top of
the agenda, it shouldn’t be surprising
that our public policies are very simi-
lar. What may be remarkable is that in
a couple passes through our policy
committees we were able to craft the
words that express our shared be-
liefs.”
The unified public policy statement
appears on pages 283–284 of this
issue.
ARMAND KEATING INSTALLED
AS PRESIDENT; ROB NEGRIN
ELECTED VICE PRESIDENT
Armand Keating, MD, chief of med-
ical services at Princess Margaret Hos-
pital/Ontario Cancer Institute, has
been installed as president of the
American Society for Blood and Mar-
row Transplantation.
Robert S. Negrin, MD, associate
professor of medicine and director of
the Division of Bone Marrow Trans-
plantation at Stanford University, is
the newly elected and installed vice
president, to become president in
2006.
The installation of officers and di-
rectors occurred at the Tandem BMT
Meetings in February in Orlando. The
election was by mail ballot among
members of the Society in January.
Re-elected and installed as secre-
tary is Daniel J. Weisdorf, MD, profes-
sor of medicine at the University of
Minnesota, director of the university’s
Adult Blood and Marrow Transplant
Program, and scientific director for
the National Marrow Donor Pro-
gram.
Newly elected and installed direc-
tors are:
• Claudio Anasetti, MD, Fred Hutchin-
son Cancer Research Center, Seattle
• Samuel M. Silver, MD, PhD, Univer-
sity of Michigan, Ann Arbor
• Robert L. Truitt, PhD, Medical Col-
lege of Wisconsin Cancer Center,
Milwaukee
Nelson J. Chao, MD, professor of
medicine and director of the Division
of Hematology at Duke University
Medical Center, Durham, North Caro-
lina, was elevated to president-elect
and will assume the presidency in
2005.
The new ASBMT president, Dr.
Keating, is director of the Division of
Hematology at the University of To-
ronto and professor and head of the
Department of Medical Oncology
and Hematology, as well as Chief of
Medical Services at Princess Margaret
Hospital/Ontario Cancer Institute. He
occupies the Gloria and Seymour Ep-
stein Chair in Cell Therapy and Trans-
plantation at the University of Toronto
and University Health Network.
Dr. Keating received his medical
degree cum laude in 1976 at the Uni-
versity of Ottawa Medical School and
completed fellowships in internal
medicine and hematology at the Uni-
versity of Toronto. He is board certi-
fied in internal medicine. He was a
fellow in oncology at the Veterans
Administration Medical Center in Se-
attle and a post-doctoral fellow at the
Fred Hutchinson Cancer Research
Center in Seattle.
Dr. Keating was a cancer research
scientist at the National Cancer Insti-
tute of Canada from 1983 to 1993
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and was appointed the first director
of the University of Toronto Autolo-
gous Bone Marrow Transplant Pro-
gram in 1986.
Dr. Keating is a founding member
of ASBMT and a counsellor for the
American Society of Hematology and
has chaired the Autologous Blood
and Marrow Transplant Registry (AB-
MTR). He continues to serve on the
executive committee of the IBMTR/
ABMTR. He is an associate editor of
Biology of Blood and Marrow Trans-
plantation and a co-editor of Bone
Marrow Transplantation. His research
interests include clinical and experi-
mental hematopoietic cell transplants
and the biology and clinical applica-
tion of marrow mesenchymal cells.
LIFETIME ACHIEVEMENT AWARD
PRESENTED TO E. DONNALL THOMAS
A pioneer in blood and marrow
transplantation for the treatment of
leukemia and other blood cancers
and diseases has been honored with
the 2004 ASBMT Lifetime Achieve-
ment Award. The recipient is E. Don-
nall Thomas, MD, 1990 Nobel Laure-
ate in Medicine and a member of the
Fred Hutchinson Cancer Research
Center, Seattle, and professor of med-
icine at the University of Washington.
The award was conferred during
the President’s Dinner at the 2004
Tandem BMT Meetings in Orlando.
Unable to attend the presentation,
Dr. Thomas sent a message on video-
tape. The award was accepted on his
behalf by Frederick Appelbaum, MD,
his colleague at the Hutchinson center.
“Donnall Thomas is one of the most
prominent and influential leaders in
our field,” Joseph Antin, MD, ASBMT
president, said in presenting the
award. “The impact of his research is
felt throughout the world as physi-
cians who trained under him or who
learned from his ground-breaking
publications have saved the lives of
many patients.”
The annual ASBMT Lifetime Achieve-
ment Award is supported by a grant
from Pfizer Inc.
Dr. Thomas studied at the Univer-
sity of Texas and at Harvard Medical
School, where he earned his medical
degree in 1946. He served at several
hospitals and research centers before
becoming a professor of medicine at
Columbia University’s College of Phy-
sicians and Surgeons in 1955, and at
the University of Washington School
of Medicine since 1963.
In 1956 Dr. Thomas performed
one of the first successful bone mar-
row transplants between two hu-
mans: a patient with leukemia and his
identical twin. Dr. Thomas adopted
methods to match the tissues of do-
nor and recipient closely enough to
minimize the patient’s rejection of the
marrow, and he developed drugs for
immune suppression. In 1969 these
refinements enabled Dr. Thomas to
perform a successful bone marrow
transplant in a patient with leukemia
from a relative who was not an iden-
tical twin. By 1990, therapies based
on his work enabled survival by more
than half of leukemia patients.
RECORD ATTENDANCE FOR ASBMT
ANNUAL MEETING; RECORDINGS
OF SESSIONS ARE AVAILABLE
Registration for the 2004 Tandem
BMT Meetings in Orlando was a
record 1,586. The previous record
was 1,426 last year.
Attendees came from 45 countries.
Abstract submissions were up by 13%
and included reports of research from
28 countries.
Abstracts for the meeting were
published in the February 2004 issue
of Biology of Blood and Marrow
Transplantation (Vol. 10, No. 2, Sup-
plement) and are posted on the
ASBMT Web site, www.asbmt.org.
The plenary and concurrent scien-
tific sessions, workshops, and oral ab-
stracts are available on audiocas-
sette—along with the conferences of
the transplant nurses, BMT pharma-
cists, clinical research associates, and
BMT center administrators. A list of
the programs for online purchase can
be found at www.CMEunlimited.
org/bmt.
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